Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Moderna's Norovirus Vaccine Trial Faces Setbacks and Extends Timeline

Moderna's phase 3 trial for its trivalent norovirus vaccine, mRNA-1403, has encountered significant challenges, leading to an extended timeline for study completion. The pharmaceutical giant is now preparing for a second Northern Hemisphere season to accrue sufficient cases for the trial.

NoahAI News11/6/2025

Eli Lilly's Eloralintide Shows Promise in Weight Loss, Advancing to Phase 3

Eli Lilly has announced impressive results from its phase 2 trial of eloralintide, an amylin agonist designed for weight loss treatment. The drug demonstrated significant efficacy, with patients experiencing up to 20.1% weight loss at 48 weeks, prompting the company to prepare for phase 3 trials starting next month.

NoahAI News11/6/2025

Registrar Corp. Expands Global Compliance Reach with Acquisition of CMC Medical Devices

Registrar Corp., a U.S.-based compliance specialist and unit of Paine Schwartz Partners, has acquired Spanish medical device consulting services provider CMC Medical Devices. This strategic move significantly broadens Registrar's global footprint in the medical device regulatory compliance sector.

NoahAI News11/6/2025

Optain Health Acquires EyePACS, Expanding AI-Powered Retinal Screening in Primary Care

Optain Health, a startup specializing in AI-powered retinal screening technology, has acquired EyePACS, a teleophthalmology network provider. This strategic move aims to broaden access to eye disease screening in primary care settings across the United States and globally.

NoahAI News11/6/2025

Evommune's $150M IPO Marks Latest Biotech Market Entry Amid Industry Recovery

Inflammation-focused biotech Evommune has successfully launched its initial public offering (IPO) on the New York Stock Exchange, raising $150 million in a move that signals growing investor confidence in the pharmaceutical sector. The California-based company's public debut follows closely on the heels of MapLight Therapeutics' recent $250 million Nasdaq entry, potentially heralding a resurgence in biotech IPOs after a period of market uncertainty.

NoahAI News11/6/2025

Novartis' Pluvicto Success Boosts Radiopharmaceutical Industry Outlook

Novartis' radioligand therapy Pluvicto has demonstrated remarkable success in the treatment of prostate cancer, signaling a potential turning point for the radiopharmaceutical industry. The Swiss pharmaceutical giant reported $564 million in Pluvicto sales for the third quarter, representing a 45% growth compared to the same period last year. This surge in sales has not only bolstered Novartis' position in the market but has also reinvigorated interest in radiopharmaceuticals across the industry.

NoahAI News11/6/2025

AstraZeneca Discontinues Multiple Drug Programs Amid Pipeline Restructuring

AstraZeneca, the UK-based pharmaceutical giant, has announced significant changes to its drug development pipeline, discontinuing several programs across various therapeutic areas. The company's third-quarter earnings report revealed the termination of multiple drug candidates, including a promising treatment for fatty liver disease and an antibody targeting a rare neurological condition.

NoahAI News11/6/2025

Dynavax Acquires Rights to Vaxart's Oral COVID-19 Vaccine in $30M Deal

Dynavax Technologies has entered into an agreement with Vaxart to acquire global rights to the latter's investigational oral COVID-19 vaccine candidate. The deal, announced on November 6, 2025, involves an upfront payment of $30 million, positioning Dynavax to evaluate phase 2b data before making a more substantial commitment to the program.

NoahAI News11/6/2025

Cryoablation Breakthrough: IceCure's ProSense System Shows Promise in Lung Cancer Treatment

IceCure Medical, an Israel-based medtech company, has reported encouraging results from a new study demonstrating the potential of its ProSense cryoablation system in treating inoperable non-small cell lung cancer (NSCLC). This development comes on the heels of the company's recent FDA approval for using the same technology in early-stage breast cancer treatment.

NoahAI News11/6/2025

Biopharma Job Market Shows Signs of Recovery Amidst Ongoing Challenges

The pharmaceutical and biotechnology job market is showing early signs of recovery, according to recent data from BioSpace, a leading life sciences career and news platform. While year-over-year job postings remain significantly lower, a slight uptick in month-over-month listings suggests a potentially stabilizing employment landscape in the sector.

NoahAI News11/6/2025

FTC Raises Concerns Over Novo Nordisk's $10 Billion Bid for Metsera Amid Fierce Competition with Pfizer

The pharmaceutical industry is witnessing a high-stakes battle for control of obesity drug developer Metsera, with Novo Nordisk and Pfizer locked in a bidding war that has now drawn scrutiny from U.S. regulators. The Federal Trade Commission (FTC) has expressed concerns about Novo Nordisk's proposed $10 billion acquisition, citing potential violations of merger laws and raising questions about the deal's structure.

NoahAI News11/6/2025

Evommune Secures $150M in IPO Amid Federal Shutdown, Advancing Immune Disorder Treatments

Evommune, a Palo Alto-based biotechnology company, has successfully priced its initial public offering (IPO) at $150 million, despite the ongoing federal government shutdown. The company, which specializes in developing treatments for immune conditions, sold nearly 9.4 million shares at $16 each and is set to begin trading on the New York Stock Exchange under the ticker symbol "EVMN".

NoahAI News11/6/2025

«1...40 41 42...67 »